疾病進展生物標記市場－策略分析與預測（2026-2035）

預計疾病進展生物標記市場將從 2026 年的 81.1 億美元成長到 2035 年的 202.3 億美元，複合年成長率為 10.7%。

疾病進展生物標記市場正經歷顯著的變革，其驅動力包括：精準醫療模式轉移、對疾病時間序列監測的日益重視，以及生物標記在臨床開發和治療策略制定中日益廣泛的應用。這一市場演變的特點在於，人們逐漸認知到，長期監測疾病進展、嚴重程度和治療反應對於最佳化患者管理、簡化臨床試驗以及實現個人化治療策略至關重要。液態生物檢體、多組體學和人工智慧 (AI) 等先進分子技術的融合，使得疾病評估更加全面和動態。隨著慢性疾病在醫療保健成本和臨床負擔中所佔比例的不斷上升，醫療保健系統正日益採用時間序列生物標記監測。此外，早期識別疾病進展能夠幫助醫生在發生不可逆的組織損傷之前調整治療性介入。製藥公司正在將生物標記終點納入臨床試驗，因為早期療效評估能夠加快臨床開發速度，並提高效率。隨著對多組體學平台、人工智慧驅動的生物標記發現和液態生物檢體技術的大量投資，疾病進展生物標記正在成為全球醫療保健系統中精準醫療的關鍵組成部分。

市場促進因素

• 精準醫療在臨床實踐中的日益普及是疾病進展生物標記市場的主要驅動力。由於精準醫療基於客觀的生物學指標制定個人化的治療策略，疾病進展生物標記已成為現代醫學的重要組成部分。鑑於疾病進展的變異性和統一治療策略的局限性，醫療機構正擴大採用基於生物標記的治療流程。這一轉變促使製藥公司在開發標靶治療的同時開發伴隨診斷，從而增加了對跨多個治療領域檢驗的疾病進展生物標記的需求。因此，疾病進展生物標記的應用持續成長。基於生物標記的臨床試驗的擴展，透過對早期療效評估的需求，進一步加速了市場成長。臨床開發越來越依賴能夠比傳統臨床終點更早提供治療療效證據的生物標記。由於分子層面的變化通常領先可觀察到的臨床結果，製藥公司正在將進展生物標記納入I-III期臨床試驗。此策略支持適應性試驗設計，進而降低研發過程中的不確定性，最佳化病患選擇，並加速法規核准。液態生物檢體技術的日益普及為非侵入性疾病監測提供了更多機會。液態生物檢體可透過微創血液採集來實現疾病的迭代監測，從而減少對組織切片檢查進行縱向評估的依賴。醫療系統正擴大將循環腫瘤DNA、循環性腫瘤細胞和其他血液來源的生物標記納入考量，因為連續監測能夠持續監測疾病進展。這種能力有助於最佳化治療方案，並促進早期發現抗藥性。監管機構對生物標記合格的支持推動了對檢驗的進展生物標記的需求。監管機構認知到生物標記是提高臨床開發效率和病人安全性的寶貴工具。標準化的生物標記評估增強了人們對其臨床效用的信心，促使監管機構擴展系統性的合格流程。

市場限制因素

• 由於缺乏針對不同患者群體的有限臨床檢驗，多種新型疾病進展生物標記的常規應用仍受到限制。缺乏可靠的檢驗數據為臨床應用帶來了不確定性。檢測標準化和檢查室調查方法的差異降低了可重複性，為廣泛的臨床應用帶來了不確定性。缺乏統一的方案削弱了可比性和臨床可靠性。儘管越來越多的科學證據支持其臨床價值，但由於新型生物標記檢測的保險報銷存在不確定性，醫療機構對其使用受到限制。保險覆蓋範圍的區域差異給診斷機構帶來了不確定性，並限制了患者的就醫途徑。不同司法管轄區的監管複雜性給尋求將新型生物標記解決方案商業化的製造商帶來了合規負擔。

對技術和生物標記類型的深入了解

• 技術發展趨勢的特徵是整合多組學體學、液態生物檢體和人工智慧驅動的發現的重要性日益凸顯。腫瘤學是這些技術的主要應用領域，因為腫瘤的生物學特性在整個治療過程中不斷變化。醫療專業人員擴大利用循環腫瘤DNA、循環性腫瘤細胞、基因測序和微量殘存疾病生物標記物，因為與傳統影像學相比，這些技術能夠更早檢測治療反應。治療過程中抗藥性突變的頻繁出現增加了對重複生物標記檢測的需求，以指導治療策略的調整。多組體學平台正在拓展我們對疾病生物學的理解，因為多種分子路徑相互作用，共同影響疾病進展。製藥公司正在投資多組體學平台，以識別更全面的生物標記特徵。液態生物檢體因其非侵入性疾病監測的優勢，尤其是在腫瘤學領域，正日益普及。細分市場分析表明，診斷實驗室是最大的終端用戶群體，因為先進的分子檢測需要專門的分析基礎設施和品管的工作流程。隨著生物標記複雜性的不斷增加，實驗室正在拓展其在新一代定序（NGS）、數位PCR、多重免疫檢測和蛋白質體學方面的能力。由於慢性疾病需要持續評估而非孤立的診斷，疾病進展監測已成為重要的臨床應用。傳統的臨床評估通常只能在不可逆的生物變化後才能檢測到疾病進展，因此，人們越來越需要能夠識別早期惡化的高靈敏度分子指標。人工智慧的整合變得日益重要，因為人工智慧可以透過分析高維度生物資料集來加速生物標記的發現。研究實驗室正擴大採用機器學習演算法，因為計算模型可以識別與疾病進展相關的可預測分子模式。

競爭格局與策略展望

• 競爭格局包括成熟的診斷和生命科學公司，以及專注於精準腫瘤學、液態生物檢體和多組體學的供應商。羅氏憑藉其藥物研發與全球最大的體外診斷業務之一，並保持著最強大的戰略地位之一。這使得羅氏能夠同時開發治療藥物和伴隨診斷產品，從而在整個藥物研發生命週期中支持精準醫療。賽默飛世爾科技憑藉其廣泛的生命科學基礎設施脫穎而出，提供支持生物標記發現、轉化研究、臨床開發和商業診斷檢測的技術，並提供涵蓋NGS、PCR、質譜、流式細胞技術、蛋白質組學和臨床診斷的組合實驗室解決方案。凱傑憑藉其整合的樣本製備技術、PCR平台、NGS解決方案、生物資訊學和伴隨診斷開發產品組合，在分子診斷領域佔據主導地位。 Guardant Health專注於精準腫瘤學和液態生物檢體技術，使其成為無創疾病進展監測領域的領導者。默克公司將生物標記開發直接整合到其藥物研發和精準醫療策略中，專注於識別有助於改善患者選擇、預測治療反應和監測疾病進展的分子體學。兩家公司都在透過在多組學平台、液態生物檢體檢測和人工智慧驅動的藥物發現工具方面的創新來擴展其產品系列。在生物標記發現和檢驗需求的推動下，診斷設備製造商、製藥公司和研究機構之間的策略合作日益增加。近期一項重大進展是，Circular Genomics公司推出了其專有的環狀RNA平台CircPath，先前發表在《自然醫學》上的研究表明，該平台在阿茲海默症早期檢測和風險分層方面具有卓越的性能。西門子醫療透過推出用於研究的全自動Atellica IM pTau217和BDTau檢測，擴展了其腦部健康研究產品組合。地理擴張仍然是關鍵的策略重點，兩家公司都將目光投向了快速成長的亞太地區和醫療基礎設施不斷完善的新興市場。

簡明結論

• 疾病進展生物標記市場預計將持續成長，這主要得益於精準醫療、技術創新和監管支援的推動。從間歇性診斷到持續性疾病監測的轉變，標誌著醫療服務模式的根本性變革。儘管臨床有效性檢驗、標準化和報銷標準差異等挑戰依然存在，但對技術、夥伴關係和證據產生的策略性投資正為市場領導帶來持續的競爭優勢。長期市場前景依然樂觀，因為疾病進展生物標記正發展成為影響全球醫療體系藥物研發、監管評估、治療最佳化和個人化醫療的重要決策工具。

本報告的主要益處：

• 深入分析：詳細分析涵蓋各個地區、客戶群、政策、社會經濟因素、消費者偏好和產業。
• 競爭格局：我們將了解主要公司的策略部署，並確定最佳的市場進入方式。
• 市場促進因素與未來趨勢：我們評估影響市場的關鍵成長要素和新興趨勢。
• 實用建議：我們支援制定策略決策，以開發新的收入來源。
• 適用於廣泛的使用者群體：非常適合新創公司、研究機構、顧問公司、中小企業和大型企業。

你用它來做什麼？

產業和市場分析、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範和影響、新產品開發以及競爭影響。

分析範圍

• 歷史資料（2021-2024 年）、基準年（2025 年）和預測資料（2026-2035 年）
• 成長機會、挑戰、供應鏈前景、法規結構、顧客行為和趨勢分析。
• 競爭對手定位、策略和市場佔有率分析
• 營收成長率及預測分析：依業務板塊及地區（國家）分類
• 企業概況（策略、產品、財務資訊、關鍵趨勢等）

目錄

第1章執行摘要

• 市場概述
• 主要分析結果
• 分析師意見
• 策略建議

第2章 分析方法

• 分析設計
• 資料收集和分析方法
• 市場規模估算
• 預測模型
• 先決條件和限制

第3章 全球疾病進展生物標記市場：概況、市場規模與預測

• 市場定義和範圍
• 疾病進展生物標記的行業概覽
• 產業變化
• 主要市場趨勢
• 實際成果值市場規模分析
• 市場預測
• 疾病負擔和臨床未滿足的需求
• 流行病學和疾病盛行率分析
• 已確診患者族群的分析
• 生物標記開發和臨床檢驗的現狀
• 生物標記在整個疾病管理過程中的應用現狀
• 伴隨生物標記和預後生物標記的生態系統

第4章 市場動態

• 市場促進因素
• 市場限制因素
• 市場機遇
• 市場挑戰

第5章 行業情勢

• 產業價值鏈分析
• 定價分析
• 還款狀態

第6章：創新趨勢

• 新型生物標記技術
• 多體學和精準醫學領域的創新
• 液態生物檢體和非侵入性生物標記的進展
• 人工智慧驅動的生物標記發現與檢驗
• 臨床試驗分析
• 疾病進展生物標記的管道分析
• 將數位健康技術應用於疾病的時間序列監測

第7章 監理情勢

• 法律規範
• 核准流程
• 合規要求

第8章 全球疾病進展生物標記市場：展望分析

• 分析：依生物標記類型
• 分析：按技術
• 分析：依檢體類型
• 分析：根據指示
• 分析：透過臨床應用
• 分析：按最終用戶

第9章 全球疾病進展生物標記市場：細分市場分析

• 依生物標誌類型
  • 分子生物標記
  • 基因生物標記
  • 蛋白質生物標記
  • 代謝體學物標誌物
  • 其他
• 透過技術
  • 分子技術
  • 蛋白質分析
  • 細胞分析
  • 其他分析技術
• 依檢體類型
  • 血
  • 血漿/血清
  • 腦脊髓液（CSF）
  • 組織
  • 其他
• 疾病指徵
  • 腫瘤學
  • 神經退化性疾病
  • 心血管疾病
  • 自體免疫疾病
  • 代謝性疾病
  • 感染疾病
  • 其他疾病指徵
• 臨床應用
  • 監測疾病進展
  • 預後評估
  • 患者分層
  • 治療反應監測
  • 其他
• 最終用戶
  • 醫院
  • 診斷檢查室
  • 學術研究機構
  • 其他

第10章 全球疾病進展生物標記市場：區域分析

• 北美洲
• 歐洲
• 亞太地區
• 南美洲
• 中東和非洲

第11章 全球疾病進展生物標記市場：國家分析

• 美國
• 加拿大
• 德國
• 英國
• 法國
• 義大利
• 西班牙
• 荷蘭
• 日本
• 中國
• 韓國
• 印度
• 澳洲
• 巴西
• 沙烏地阿拉伯

第12章 競爭格局

• 市佔率分析
• 策略趨勢
• 企業合併、商業夥伴關係和合作
• 新產品發布

第13章：公司簡介

• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• QIAGEN NV
• Guardant Health Inc.
• Bio-Rad Laboratories, Inc.
• Merck & Co., Inc.
• Danaher Corporation
• Novartis AG
• Siemens Healthineers AG
• Abbott Laboratories

第14章 全球疾病進展生物標記市場：商業預測分析

第15章 投資與資金籌措分析

• 創業投資趨勢
• 政府資金
• 研發投資

第16章：未來展望

• 主要成長機遇
• 未來產業趨勢

The Disease Progression Biomarkers Market is expected to grow at a CAGR of 10.7% from a market value of USD 8.11 billion in 2026 to USD 20.23 billion in 2035.

The disease progression biomarkers market is undergoing significant transformation driven by the paradigm shift toward precision medicine, the growing emphasis on longitudinal disease monitoring, and the increasing integration of biomarkers into clinical development and therapeutic decision-making. The market's evolution is characterized by the recognition that measuring disease evolution, severity, and therapeutic response over time is essential for optimizing patient management, improving clinical trial efficiency, and enabling personalized treatment strategies. The convergence of advanced molecular technologies, including liquid biopsy, multi-omics platforms, and artificial intelligence, is enabling more comprehensive and dynamic disease assessment. Healthcare systems are increasingly adopting longitudinal biomarker monitoring because chronic diseases account for a growing proportion of healthcare expenditure and clinical burden, and earlier identification of disease progression enables physicians to modify therapeutic interventions before irreversible tissue damage occurs. Pharmaceutical companies are integrating biomarker endpoints into clinical trials because earlier efficacy assessment supports faster and more efficient clinical development. The market is witnessing significant investment in multi-omics platforms, AI-enabled biomarker discovery, and liquid biopsy technologies, positioning disease progression biomarkers as a critical component of precision medicine across global healthcare systems.

Market Drivers

• The increasing integration of precision medicine into clinical practice represents the primary driver for the disease progression biomarkers market. Precision medicine relies on objective biological indicators to personalize therapeutic decisions, making disease progression biomarkers essential components of modern healthcare. Healthcare providers are increasingly adopting biomarker-guided treatment algorithms because heterogeneous disease progression limits the effectiveness of uniform treatment strategies. This transition is encouraging pharmaceutical companies to develop companion diagnostics alongside targeted therapies, strengthening demand for validated progression biomarkers across multiple therapeutic areas, resulting in sustained growth in disease progression biomarker utilization. The expanding biomarker-based clinical trials are further accelerating market growth through demand for earlier efficacy assessment. Clinical development increasingly depends on biomarkers that provide earlier evidence of therapeutic effectiveness than traditional clinical endpoints. Drug developers are incorporating progression biomarkers into Phase I-III clinical studies because molecular changes frequently precede observable clinical outcomes. This strategy reduces development uncertainty while supporting adaptive trial designs that improve patient selection and accelerate regulatory evaluation. The rising adoption of liquid biopsy technologies is expanding opportunities for non-invasive disease monitoring. Liquid biopsy enables repeated disease monitoring through minimally invasive blood sampling, reducing dependence on tissue biopsies for longitudinal assessment. Healthcare systems are increasingly implementing circulating tumor DNA, circulating tumor cells, and other blood-based biomarkers because serial testing provides continuous insights into disease evolution. This capability strengthens treatment optimization while supporting earlier identification of therapeutic resistance. Regulatory support for biomarker qualification is strengthening demand for validated progression biomarkers. Regulatory agencies recognize biomarkers as valuable tools that improve clinical development efficiency and patient safety. Agencies are expanding structured qualification pathways because standardized biomarker evaluation enhances confidence in clinical utility.

Market Restraints

• Limited clinical validation across diverse patient populations continues restricting routine implementation of several emerging disease progression biomarkers. The lack of robust validation data creates uncertainty for clinical implementation. Variability in assay standardization and laboratory methodologies reduces reproducibility, creating challenges for widespread clinical adoption. The lack of harmonized protocols reduces comparability and clinical confidence. Reimbursement uncertainty for novel biomarker assays limits healthcare provider utilization despite growing scientific evidence supporting clinical value. Inconsistent coverage across regions creates uncertainty for diagnostic providers and limits patient access. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new biomarker solutions.

Technology and Biomarker Type Insights

• The technology landscape is characterized by the growing importance of integrated multi-omics platforms, liquid biopsy, and AI-enabled discovery. Oncology represents the leading application because tumor biology evolves continuously throughout treatment. Healthcare providers are increasingly utilizing circulating tumor DNA, circulating tumor cells, genomic sequencing, and minimal residual disease biomarkers because serial molecular assessment detects treatment response earlier than conventional imaging. Resistance mutations frequently emerge during therapy, creating demand for repeated biomarker testing that guides treatment modification. Multi-omics platforms are expanding understanding of disease biology because multiple molecular pathways collectively influence disease progression. Pharmaceutical companies are investing in multi-omics platforms that identify more comprehensive biomarker signatures. Liquid biopsy is expanding for non-invasive disease monitoring, particularly in oncology. The segment analysis reveals that diagnostic laboratories represent the largest end-user segment because advanced molecular testing requires specialized analytical infrastructure and quality-controlled workflows. Laboratories are expanding NGS, digital PCR, multiplex immunoassays, and proteomic capabilities as biomarker complexity continues increasing. Disease progression monitoring constitutes the primary clinical application because chronic diseases require continuous assessment rather than isolated diagnosis. Conventional clinical evaluations often detect progression after irreversible biological changes occur, creating demand for sensitive molecular indicators capable of identifying early deterioration. The integration of AI is becoming increasingly important because AI improves biomarker discovery by analyzing high-dimensional biological datasets. Research organizations are increasingly deploying machine learning algorithms because computational models identify predictive molecular patterns associated with disease progression.

Competitive and Strategic Outlook

• The competitive landscape features established diagnostics and life science companies alongside specialized precision oncology, liquid biopsy, and multi-omics providers. Roche maintains one of the strongest strategic positions because it combines pharmaceutical development with one of the world's largest in vitro diagnostics businesses, enabling Roche to develop therapeutics and companion diagnostics simultaneously, supporting precision medicine throughout the drug development lifecycle. Thermo Fisher Scientific differentiates itself through its broad life sciences infrastructure, supplying technologies that support biomarker discovery, translational research, clinical development, and commercial diagnostic testing, providing integrated laboratory solutions spanning NGS, PCR, mass spectrometry, flow cytometry, proteomics, and clinical diagnostics. QIAGEN occupies a leading position in molecular diagnostics because its portfolio integrates sample preparation technologies, PCR platforms, NGS solutions, bioinformatics, and companion diagnostic development. Guardant Health distinguishes itself through its exclusive focus on precision oncology and liquid biopsy technologies, positioning the company as a leader in non-invasive disease progression monitoring. Merck integrates biomarker development directly into its pharmaceutical research and precision medicine strategy, focusing on identifying molecular biomarkers that improve patient selection, predict therapeutic response, and monitor disease progression. Companies are pursuing product portfolio expansion through innovation in multi-omics platforms, liquid biopsy assays, and AI-enabled discovery tools. Strategic collaborations between diagnostic manufacturers, pharmaceutical companies, and research institutions are increasing, driven by the need for biomarker discovery and validation. Recent key developments include Circular Genomics launching CircPath, its proprietary circular RNA platform, following a Nature Medicine study showing strong performance for early Alzheimer's detection and risk stratification. Siemens Healthineers expanded its brain health research portfolio with fully automated Atellica IM pTau217 and BDTau assays for research use. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

• The disease progression biomarkers market is positioned for sustained growth driven by the convergence of precision medicine, technological innovation, and regulatory support. The transition from episodic diagnosis toward continuous disease monitoring represents a fundamental shift in healthcare delivery. While challenges related to clinical validation, standardization, and reimbursement variability persist, strategic investments in technology, partnerships, and evidence generation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with disease progression biomarkers evolving into essential decision-making instruments that influence drug development, regulatory evaluation, treatment optimization, and personalized patient care across global healthcare systems.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Global Disease Progression Biomarkers Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Disease Progression Biomarkers Industry Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2035)
• 3.7 Disease Burden & Unmet Clinical Needs
• 3.8 Epidemiology & Disease Prevalence Analysis
• 3.9 Diagnosed Patient Population Analysis
• 3.10 Biomarker Development & Clinical Validation Landscape
• 3.11 Biomarker Adoption Across Disease Management Continuum
• 3.12 Companion and Prognostic Biomarker Ecosystem

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Biomarker Technologies
• 6.2 Multi-Omics and Precision Medicine Innovations
• 6.3 Liquid Biopsy and Non-Invasive Biomarker Developments
• 6.4 AI-Enabled Biomarker Discovery & Validation
• 6.5 Clinical Trial Analysis
• 6.6 Disease Progression Biomarker Pipeline Analysis
• 6.7 Digital Health Integration for Longitudinal Disease Monitoring

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Global Disease Progression Biomarkers Market Landscape Analysis

• 8.1 Analysis by Biomarker Type
• 8.2 Analysis by Technology
• 8.3 Analysis by Sample Type
• 8.4 Analysis by Disease Indication
• 8.5 Analysis by Clinical Application
• 8.6 Analysis by End User

9. Global Disease Progression Biomarkers Market Segment Analysis (2021-2035)

• 9.1 By Biomarker Type
  • 9.1.1 Molecular Biomarkers
  • 9.1.2 Genetic Biomarkers
  • 9.1.3 Protein Biomarkers
  • 9.1.4 Metabolomic Biomarkers
  • 9.1.5 Others
• 9.2 By Technology
  • 9.2.1 Molecular Technologies
  • 9.2.2 Protein Analysis
  • 9.2.3 Cell Analysis
  • 9.2.4 Other Analytical Technologies
• 9.3 By Sample Type
  • 9.3.1 Blood
  • 9.3.2 Plasma & Serum
  • 9.3.3 Cerebrospinal Fluid (CSF)
  • 9.3.4 Tissue
  • 9.3.6 Others
• 9.4 By Disease Indication
  • 9.4.1 Oncology
  • 9.4.2 Neurodegenerative Diseases
  • 9.4.3 Cardiovascular Diseases
  • 9.4.4 Autoimmune Diseases
  • 9.4.5 Metabolic Disorders
  • 9.4.6 Infectious Diseases
  • 9.4.7 Other Disease Indications
• 9.5 By Clinical Application
  • 9.5.1 Disease Progression Monitoring
  • 9.5.2 Prognosis Assessment
  • 9.5.3 Patient Stratification
  • 9.5.4 Treatment Response Monitoring
  • 9.5.5 Others
• 9.6 By End User
  • 9.6.1 Hospitals
  • 9.6.2 Diagnostic Laboratories
  • 9.6.3 Academic & Research Institutes
  • 9.6.4 Others

10. Global Disease Progression Biomarkers Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Global Disease Progression Biomarkers Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Netherlands
• 11.9 Japan
• 11.10 China
• 11.11 South Korea
• 11.12 India
• 11.13 Australia
• 11.14 Brazil
• 11.15 Saudi Arabia

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 F. Hoffmann-La Roche Ltd.
  • 13.1.1 Company Overview
  • 13.1.2 Financials
  • 13.1.3 Product Portfolio
  • 13.1.4 Recent Developments
• 13.2 Thermo Fisher Scientific Inc.
• 13.3 QIAGEN N.V.
• 13.4 Guardant Health Inc.
• 13.5 Bio-Rad Laboratories, Inc.
• 13.6 Merck & Co., Inc.
• 13.7 Danaher Corporation
• 13.8 Novartis AG
• 13.9 Siemens Healthineers AG
• 13.10 Abbott Laboratories

14. Global Disease Progression Biomarkers Market Commercial Forecast Analysis

• 14.1 Forecast by Biomarker Technology Platform
• 14.2 Forecast by Disease Indication
• 14.3 Forecast by Clinical Application
• 14.4 Forecast by End User

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends